NEWS: FDA Doesn’t Approve Contrave

Contrave is a combination weight loss pill manufactured by Orexigen. It is a pill that combines naltrexone and bupropion to achieve weight loss. Despite the promising combination of these two drugs, the FDA still doesn’t approve Contrave unless Orexigen will conduct a new clinical trial that will evaluate the cardiovascular risks of Contrave.

Orexigen has already conducted clinical studies about the weight loss benefits of Contrave. However, the four clinical trials have fall short on the standards of FDA. Aside from that, these clinical trials have proven that those who have been taking Contrave who have less than 5 percent of weight loss have experienced an increase in blood pressure. Blood pressure increase and cardiovascular conditions were not included in the drug’s adverse effects but the results of the clinical trials have proven otherwise.

Because of these findings, FDA requires Orexigen to conduct new clinical trial for the effectiveness of the drug in terms of weight loss as well as the cardiovascular risks for taking this pill combination. Orexigen didn’t announce any plans of conducting clinical trials as of the moment.

Related Posts:

Another Diet Pill Can Cause Heart Problems According to FDA

Drugmaker Protests for the Premature Halting of the Trial for the Weight Loss Drug

NEWS: US Plans to Pull Meridia Off the Market

NEWS: FDA Finally Rejected Qnexa

NEWS: Meridia withdrawn by Abbott in US and Canada